Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 250
Single User License Price INR 17250
Corporate User License Price USD 750
Corporate User License Price INR 51750
Site License Price USD 500
Site License Price INR 34500
Request a Quote

Report Title

OptiNose US Inc (OPTN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Quote Request for License Type
License Type Price  
Single User License USD 250
Site License USD 500
Enterprise Wide License USD 750
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

OptiNose US Inc (OPTN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile


Quote Request for License Type
License Type Price  
Single User License USD 250
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

OptiNose US Inc (OPTN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

OptiNose US Inc (OPTN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile



Executive Summary

Summary

OptiNose US Inc (OptiNose) is a specialty pharmaceutical company that develops and delivers new pipeline drugs through intranasal deposition of medications. The company offers products such as XHANCE fluticasone propionate and ONZETRA sumatriptan nasal powder. Its products are used in the therapeutic areas of nasal inflammatory diseases, nasal congestion and obstruction, chronic rhinosinusitis, facial pain and pressure, drainage and postnasal drip, nasal polyps, autism, narcolepsy and Parkinson's diseases. OptiNose develops powder delivery device with a disposable drug-containing section and liquid delivery device for medication-carrying airflow into nasal cavity. The company also develops exhalation delivery system technology used for the treatment of neurological or psychiatric disorders, and central nervous system disorders. It has operations in the US, Norway and the UK. OptiNose is headquartered in Yardley, Pennsylvania, the US.

OptiNose US Inc (OPTN)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

OptiNose US Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

OptiNose US Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

OptiNose US Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

OptiNose US Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

OptiNose US Inc, Medical Devices Deals, 2012 to YTD 2018 9

OptiNose US Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

OptiNose US Inc, Pharmaceuticals & Healthcare, Deal Details 11

Venture Financing 11

OptiNose Raises USD37 Million in Series D Financing 11

Optinose Raises USD30 Million in Venture Financing 12

Private Equity 13

Optinose to Raise USD100 Million in Private Placement of Notes Due 2023 13

Partnerships 15

OptiNose US Enters Into Collaboration with Oslo University Hospital, SINTEF and Smerud Medical Research International 15

Equity Offering 16

Optinose Raises USD55.6 Million in Public Offering of Share 16

Optinose to Raise Funds through Public Offering of Shares 18

OptiNose Raises USD0.05 Million in Private Placement of Shares up on Exercise of Warrants 19

OptiNose Raises USD138 Million in IPO of Shares 20

Debt Offering 22

Optinose Raises USD15 Million in Private Placement of 17% Notes Due 2020 22

Optinose Raises USD15 Million in Private Placement of 17% Notes Due 2017 23

OptiNose US Inc-Key Competitors 24

OptiNose US Inc-Key Employees 25

OptiNose US Inc-Locations And Subsidiaries 26

Head Office 26

Other Locations & Subsidiaries 26

Recent Developments 27

Financial Announcements 27

Aug 14, 2018: Optinose reports second quarter 2018 financial results and recent operational highlights 27

May 14, 2018: Optinose Announces First Quarter 2018 Financial Results 29

Mar 13, 2018: Optinose Announces Fourth Quarter and Full Year 2017 Financial Results 31

Nov 27, 2017: Optinose Reports Third Quarter 2017 Financial Results and Recent Operating Highlights 33

Corporate Communications 35

Feb 22, 2018: Optinose names Sandra L. Helton as Director and Chairperson of the Company's Audit Committee 35

Feb 09, 2017: OptiNose appoints chief legal officer 36

Appendix 37

Methodology 37

About GlobalData 37

Contact Us 37

Disclaimer 37

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

List of Figures

OptiNose US Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

OptiNose US Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

OptiNose US Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

OptiNose US Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

OptiNose US Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

OptiNose US Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

OptiNose US Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

OptiNose US Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

OptiNose US Inc, Medical Devices Deals, 2012 to YTD 2018 9

List of Tables

OptiNose US Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

OptiNose US Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

OptiNose US Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

OptiNose US Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

OptiNose US Inc, Deals By Therapy Area, 2012 to YTD 2018 8

OptiNose US Inc, Medical Devices Deals, 2012 to YTD 2018 9

OptiNose US Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

OptiNose Raises USD37 Million in Series D Financing 11

Optinose Raises USD30 Million in Venture Financing 12

Optinose to Raise USD100 Million in Private Placement of Notes Due 2023 13

OptiNose US Enters Into Collaboration with Oslo University Hospital, SINTEF and Smerud Medical Research International 15

Optinose Raises USD55.6 Million in Public Offering of Share 16

Optinose to Raise Funds through Public Offering of Shares 18

OptiNose Raises USD0.05 Million in Private Placement of Shares up on Exercise of Warrants 19

OptiNose Raises USD138 Million in IPO of Shares 20

Optinose Raises USD15 Million in Private Placement of 17% Notes Due 2020 22

Optinose Raises USD15 Million in Private Placement of 17% Notes Due 2017 23

OptiNose US Inc, Key Competitors 24

OptiNose US Inc, Key Employees 25

OptiNose US Inc, Subsidiaries 26

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

OptiNose US Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand

person